CritiTech Shows Small Particle Success

August 31, 2005

Lawrence, Kan. - CritiTech announced today that it has entered into an agreement to perform feasibility studies for the development of nano/micro particle compounds with a major international pharmaceutical company. Previously, CritiTech has successfully produced small particle compounds for this company.

“We are encouraged by the continued interest and support demonstrated by this major company in using CritiTech’s proprietary technology to help solve some of their drug delivery and development challenges,” said CEO and President Sam Campbell.

With the establishment of its new research and commercial lab facility located at 4950 Research Park Way, Lawrence, Kansas, CritiTech intends to expand its outreach to the pharmaceutical industry to help address their drug delivery and development needs. CritiTech has successfully performed feasibility work for other pharmaceutical companies and currently has several ongoing projects.

CritiTech provides critical drug delivery and development technology for the pharmaceutical industry. CritiTech produces fine-particle pharmaceuticals including nanoparticle pharmaceuticals using patented technologies developed at the University of Kansas. The processes use compressed carbon dioxide as the processing medium to produce relatively residue-free and uniform drug microparticles and coatings.

The pharmaceutical industry has exhibited substantial interest in processes that produce improved formulations using nanoparticulate drugs in order to extend the patent life of an existing drug or to enable the delivery of a poorly soluble compound. CritiTech has also successfully used its proprietary technology to coat medicinal agents either on small particle drugs for improved drug delivery or as a thin film on implantable medical devices such as cardiac stents. The Nanotax™ ovarian cancer drug is the first drug to be announced under the company’s drug development program.